Published in Cancer on April 15, 2010
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology (2015) 2.81
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology (2012) 2.33
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res (2012) 2.17
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist (2012) 1.79
Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care (2014) 1.68
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst (2015) 1.58
The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol (2014) 1.57
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist (2013) 1.41
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) (2014) 1.38
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control (2012) 1.04
Metabolic roles of AMPK and metformin in cancer cells. Mol Cells (2013) 1.02
Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore) (2015) 1.02
Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol (2014) 1.01
Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol (2013) 1.00
Lessons from mouse models of high-fat diet-induced NAFLD. Int J Mol Sci (2013) 0.97
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma. Oncologist (2012) 0.97
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol (2015) 0.96
Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol (2013) 0.94
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog (2013) 0.93
Insulin resistance and chronic liver disease. World J Hepatol (2011) 0.88
Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. Cancer Causes Control (2012) 0.87
Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area. PLoS One (2013) 0.86
Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol (2015) 0.85
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab (2011) 0.83
Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol (2015) 0.83
Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer (2014) 0.83
Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol (2014) 0.83
Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan. Gastric Cancer (2012) 0.82
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci (2015) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol (2013) 0.81
From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer (2016) 0.81
NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol (2016) 0.81
Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS One (2016) 0.81
Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol (2016) 0.81
Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol (2015) 0.80
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci (2015) 0.80
Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One (2015) 0.79
Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma: mini-review. J Diabetes Metab Disord (2014) 0.79
Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol (2015) 0.79
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterol Res Pract (2015) 0.79
Glycogen synthase kinase-3β is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma. PLoS One (2014) 0.78
Metformin and cancer. Rev Diabet Stud (2014) 0.78
Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. World J Gastroenterol (2016) 0.77
Effect of pioglitazone on outcome following curative treatment for hepatocellular carcinoma in patients with hepatitis C virus infection: A prospective study. Mol Clin Oncol (2014) 0.77
Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma. World J Gastroenterol (2013) 0.76
Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J (2015) 0.76
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep (2016) 0.76
Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases? Gastroenterology (2016) 0.76
A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. Pharmaceuticals (Basel) (2016) 0.75
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine (Baltimore) (2017) 0.75
Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore) (2017) 0.75
Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation. Cancer Cell Int (2017) 0.75
Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol (2016) 0.75
Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink. Int J Cancer (2015) 0.75
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med (2017) 0.75
Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis. Int J Clin Oncol (2015) 0.75
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care (1998) 18.69
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Economic costs of diabetes in the US in 2002. Diabetes Care (2003) 8.92
Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med (1999) 7.99
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol (2004) 5.29
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med (2000) 5.13
Self-report and medical record report agreement of selected medical conditions in the elderly. Am J Public Health (1989) 4.32
Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs (2005) 4.20
The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol (2006) 4.17
Selection of controls in case-control studies. I. Principles. Am J Epidemiol (1992) 3.94
Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol (1992) 3.80
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst (1997) 3.57
Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc (2004) 3.52
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut (2005) 2.90
Selection of controls in case-control studies. III. Design options. Am J Epidemiol (1992) 2.88
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst (1996) 2.78
Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 2.66
Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology (2006) 2.49
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer (2004) 2.13
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol (2008) 2.02
Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia (2008) 1.79
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle (2009) 1.66
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology (2009) 1.62
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther (2004) 1.61
Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2004) 1.60
The management of diabetes in patients with advanced cancer. J Pain Symptom Manage (1997) 1.51
Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst (1991) 1.50
The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis (2002) 1.43
Diabetes increases the risk of acute hepatic failure. Gastroenterology (2002) 1.39
Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD. Am J Kidney Dis (2008) 1.33
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol (2009) 1.33
Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol (2008) 1.31
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med (2006) 1.26
An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol (2004) 1.26
Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev (1998) 1.22
Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res (1996) 1.17
Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer (2008) 1.16
Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology (1998) 1.16
The development of a comprehensive, institution-based patient risk evaluation program: II. Validity and reliability of questionnaire data. Am J Prev Med (1988) 1.14
Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med (2004) 1.13
Liver disease in patients with diabetes mellitus. J Clin Gastroenterol (2006) 1.13
Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care (2006) 1.11
Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol (2007) 1.04
Hyperglycemia decreases mitochondrial function: the regulatory role of mitochondrial biogenesis. Toxicol Appl Pharmacol (2007) 1.03
Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology (1997) 1.01
The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract (2007) 0.93
Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther (2005) 0.88
Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. Hepatol Res (2007) 0.86
Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology (2005) 0.86
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
The Arabidopsis Information Resource (TAIR): gene structure and function annotation. Nucleic Acids Res (2007) 14.24
Pancreatic cancer. Lancet (2004) 11.63
The Arabidopsis Information Resource (TAIR): improved gene annotation and new tools. Nucleic Acids Res (2011) 8.18
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Metastatic patterns in adenocarcinoma. Cancer (2006) 4.16
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA (2009) 3.86
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) (2009) 3.55
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol (2004) 3.10
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99
Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.96
Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. Proc Natl Acad Sci U S A (2006) 2.91
Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol (2003) 2.85
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol (2009) 2.69
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg (2002) 2.62
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg (2009) 2.44
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Systematic use of an intraoperative air leak test at the time of major liver resection reduces the rate of postoperative biliary complications. J Am Coll Surg (2013) 2.36
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene (2004) 2.35
Preoperative portal vein embolization for extended hepatectomy. Ann Surg (2003) 2.33
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol (2011) 2.28